Dishman Pharma ties up with S Arabia-based Takamul

New Delhi, Dec 24 (UNI) Dishman Pharmaceuticals and Chemicals Ltd has said it has tied up with Saudi Arabia-based Takamul Investments Holding company (Takamul) to manufacture hospital disinfectant formulations, Anti-cancer Drug formulations and Dry Powder inhaler (DPI).

The technology for the disinfectant and DPI will be provided by the company and technology for anticancer formulations will be provided by Switzerland-based Carbogen-Amcis AG, a step-down subsidiary of the company.

Takamul will discuss with Saudi Arabian formulation companies to join this JV arrangement, so that the it can utilise the marketing and supply chain of such pharma companies.

As per the report given by the Capital Advisory Group, Takamul's parent group, Saudi Arabian inhaler market is in excess of 250 million dollars and other Gulf Cooperation Council (GOC) nations have similar market aggregating to half million dollars.

UNI DKS SBA HT1244